🇺🇸 FDA
Patent

US 7816087

Gene expressed in prostate cancer and methods of use

granted A61KA61K39/00A61P

Quick answer

US patent 7816087 (Gene expressed in prostate cancer and methods of use) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Oct 14 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Oct 19 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 14 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K39/00, A61P, A61P35/00